TriangleSelpercatinib Monotherapy (NCT06458036)
Selpercatinib Monotherapy trial for Differentiated Thyroid Cancer (NCT06458036). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged two to twenty-five with differentiated thyroid cancer after thyroidectomy, lung metastases, and an activating RET fusion or mutation. Previous systemic thyroid-cancer therapy is excluded; prior radioactive iodine is allowed.
The idea: selpercatinib blocks RET growth signaling. Researchers test whether six months of treatment increases iodine uptake and improves response to subsequent radioactive iodine. Selpercatinib continues five days afterward; progression during treatment prompts earlier iodine therapy and stopping selpercatinib.
This phase 2 study plans 13 patients. Theodore Laetsch leads at Children's Hospital of Philadelphia; three US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.